Atlas Trials

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

Clinical trial NCT02573740 · TERMINATED

Trial details

NCT number
NCT02573740
Sponsor
AbbVie
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Alzheimer's DiseaseMild Cognitive Impairment
Start date
2015-12-01
Primary completion
2016-06-01
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.